[ China Pharmaceutical Network Technology News ] According to relevant data, the number of Chinese patients with diabetes has ranked first in the world. At present, 50.1% of adults (about 493 million) in China have pre-diabetes, of which about one-fifth to one-third have become diabetics, totaling about 119 million. Others may develop cardiovascular and cerebrovascular diseases, Alz. Patients with other metabolic syndromes such as Hammer disease and estrogen disorders are a big market worthy of attention.
(Yue sugar intends to use AI technology to help users predict postprandial blood glucose. Source: Baidu Pictures)
In 2015, the Israeli research team released a study on the use of machine learning to predict postprandial blood glucose, and concluded that a personalized nutritional diet structure can greatly stabilize postprandial blood glucose fluctuations, causing much concern.
Two years later, Yuetang hopes to use AI technology to establish a Chinese model of postprandial blood glucose response prediction, to help users predict postprandial blood glucose, find a suitable diet and exercise, and is currently working with a top three hospital, related products. Or is expected to launch this year.
In this research and development of Yuetang, mainly based on precision medicine and big data blood sugar management, affiliated to Beijing Yueyou Bomai Technology Co., Ltd., the company was incorporated in 2011, the product project was completed at the end of 2014, bata version in 2015 Going online at the end of May. Founder Yang Yufeng previously revealed that the product has more than 1.2 million users.
The product form of Yuetang includes APP and data analysis report. APP includes customer-side product “Yuetang†and administrator-side product “Home Medical Poâ€, which is mainly used by community hospitals. On the client-side APP, Yuetose monitors, tracks and intervenes in the lifestyle of the diet, exercise and nutritional supplements. Using artificial intelligence to make postprandial blood glucose prediction is an important demand point for diet monitoring and blood glucose management. It is also an important tool for opening C-side software and hardware sales, providing accurate personalized services and product sales in the future.
Before implementing postprandial blood glucose prediction, the team also hopes to use artificial intelligence related technology to enhance the user experience of the product. For example, the team recently used deep learning techniques to identify recipes and simplify the user's use complexity. Just take a photo to know the impact of food intake on blood sugar fluctuations (called sugar dots in APP).
36æ°ª has also been tested in beta. The number of dishes that can be identified is not enough to cover common dishes. Yang Yufeng told 36æ°ª that the current recognition accuracy can be 90%, which is the upper limit of the current theoretical recognition rate. A major breakthrough in Chinese recognition. The team's next goal is to increase the recognition accuracy to 95%. It is expected that the function will be extended to daily home cooking when the feature is launched in June.
Compared with the identification of artificial intelligent dishes on the market, the great advantage of Yuetang is that it has accumulated thousands of food ingredients and sugar point data in the past. This allows the team to directly give the user the sugar point of the food after identifying the dish, helping the user to directly convert the sugar point, and more convenient to control the diet and exercise.
However, similar to other companies that manage chronic diseases, it is not easy to rely solely on the C-side for commercialization. In the past year, Yuetang is also trying to sell other To B business models other than supporting products (including measuring equipment, genes, food, nutrition, etc.) to the C-end.
Although the willingness of C-terminal chronic disease users to pay for software and services is not strong, but B-end customers such as the Health Planning Commission and hospitals are willing to pay for the cost of medical insurance, improve the efficiency of medical staff, and quality. Among them, at this stage, the focus of chronic disease management is in community hospitals, and is supported by doctors in the top three hospitals. However, the relevant medical personnel have heavy tasks, and software can reduce part of the workload. The team predicts that this year's annual income is expected to be around 26 million yuan.
In China, the ceiling of medical service companies is not high. The financial reports of listed companies show that the annual income of quality companies in related fields is only about several hundred million yuan. Therefore, the team also hopes to join the C-end market in the future. At the same time, I hope that after the postprandial blood glucose prediction technology is mature, it will be able to open up commercial closed loops such as blood glucose meter sales, blood glucose monitoring and prediction services, software intervention, and personalized customized nutrition sales.
According to relevant data, the number of Chinese patients with diabetes has ranked first in the world. At present, 50.1% of adults (about 493 million) in China have pre-diabetes (referred to as “pre-sugarâ€), of which about one-fifth to one-third have become diabetic patients, totaling about 119 million, and others may develop into Patients with other metabolic syndromes such as cardiovascular and cerebrovascular diseases, Alzheimer's disease, and estrogen disorders are a big market worthy of attention.
National policies are also increasingly concerned about chronic diseases such as diabetes. In recent years, the “Healthy China 2030†planning outline, the “13th Five-Year Plan†health and health plan, and the “Guiding Opinions on Promoting Family Doctor Contracting Services†have been introduced.
Manhole & Manway
Round Manway,Round Manway Atmospheric Pressure,Manhole Cover,Hygienic Square Manway Cover
Wenzhou Gaoya Light Industry Machinery Co.,ltd. , https://www.hongyafitting.com